Otsuka's centanafadine faces July 24 FDA verdict after positive ADHD anxiety data
The FDA reviews centanafadine for ADHD under Priority Review as Otsuka's separate Phase 3b trial in comorbid anxiety just cleared its endpoint, adding supportive data ahead of the decision.
Executive Summary
- The FDA is set to rule on centanafadine for ADHD in children, adolescents, and adults by a fixed date days away, under a Priority Review that signals the agency views the unmet need as substantial.
- A separate, completed Phase 3 trial in a comorbid anxiety population met its primary endpoint against placebo, adding evidence during the review window rather than resolving the review itself.
- Centanafadine works through a mechanism, blocking reuptake of three neurotransmitters at once, that no other approved ADHD drug shares, making the approval decision a test of a genuinely different pharmacology rather than a follow-on stimulant or non-stimulant entry.
- A clean approval would open the broadest requested label in the class, covering pediatric through adult populations, while a restricted label or delay would turn attention to which population or evidence gap the agency flagged.
The catalyst
Otsuka Pharmaceutical Development & Commercialization and Otsuka Pharmaceutical Co., Ltd. are awaiting an FDA decision on centanafadine, an investigational norepinephrine, dopamine, and serotonin reuptake inhibitor, for the treatment of ADHD in children, adolescents, and adults. The FDA granted the application Priority Review and set a Prescription Drug User Fee Act target action date of July 24, 2026, compressing the standard review timeline to signal an unmet need the agency wants addressed faster. The application is under review as of the current date, with the decision still pending. OtsukaOtsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid AnxietyJun 25, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
New supportive data
Otsuka disclosed on June 25, 2026 that a Phase 3b trial (NCT06973577) evaluating centanafadine XR 280 mg once daily in adults with ADHD and comorbid generalized anxiety disorder and/or social anxiety disorder met its primary endpoint. Patients on centanafadine improved on the Adult Investigator Symptom Rating Scale by a mean of -18.5 points versus -12.6 for placebo at week 8, a treatment difference of -5.87 points (p<0.0001). The key secondary endpoint, change in the Hamilton Anxiety Rating Scale, also separated from placebo (-12.5 versus -10.6, difference -1.92, p=0.02). The trial enrolled 315 adults and completed with the most frequent adverse events, nausea, decreased appetite, diarrhea, insomnia, dry mouth and vomiting, occurring at rates the company described as consistent with centanafadine's known profile. NCT06973577+1P3b Short-term Study of CTN in Patients With ADHD and Comorbid AnxietyNCT06973577Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid AnxietyJun 25, 2026
Trial conduct
The comorbid-anxiety trial was randomized, double-blind, and placebo-controlled, enrolling adults 18 to 65 with confirmed ADHD and generalized or social anxiety disorder, and it completed on schedule after its primary completion date moved from September 2027 to April 2026 as enrollment finished ahead of an earlier projection. Enrollment landed at 315, in line with the original target, and the status change from active to completed followed the routine sequence for a trial that finished on time. None of this bears on the pending FDA decision itself, since the anxiety-comorbidity trial is a supportive dataset disclosed during the review period rather than the trial underlying the original submission. NCT06973577P3b Short-term Study of CTN in Patients With ADHD and Comorbid AnxietyNCT06973577
The competitive position
Centanafadine's mechanism, blocking the dopamine, norepinephrine, and serotonin transporters together, has no other approved or late-stage ADHD drug sharing all three targets. Stimulant and non-stimulant options dominate the approved landscape, and the ADHD target field has cooled overall, with target-level trial activity down to 28 recent trials against 534 older ones. A triple-mechanism approval would be the first of its kind in the indication rather than an incremental entry against an established comparator class.
What the decision resolves
A Priority Review timeline and a label request spanning children, adolescents, and adults make this a binary outcome with a broad population at stake. An approval clears the mechanism for use across the full requested age range; a restricted label would narrow that population to a subset the agency judged better supported; a Complete Response Letter would shift the question to what specific gap, whether in the application's evidence package or elsewhere, the agency requires closed before resubmission. OtsukaOtsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid AnxietyJun 25, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.